Description of Individual Radiosensitivity With Molecular Biomarkers in a Pediatric Oncology Population

Not Applicable

Terminated

• Conditions: Cancer-related Problem/Condition
• Interventions: Other: skin biopsy

• Registration Number: NCT02827552
• Lead Sponsor: Institut de Cancérologie de Lorraine

Brief Summary

This study aims to explore prospectively the distribution of individual radiosensitivity in the pediatric population and to determine the predictive power of individual radiosensitivity biomarkers from an immunofluorescence technique on primary dermal fibroblasts

Detailed Description

900 children and adolescents benefit from radiation each year in France. The mean age at diagnosis is 5 years; life expectancy for the 80% of them who could cure is long, and the incidence of radiation-related acute and mainly late complications - not evaluated to date - could exceed that of adults. Dysfunction of irradiated organs and growth disorders are specific to the pediatric subpopulation. Individual radiosensitivity of children and adolescents is unknown at this time, probably with large variability depending on the age when considering the changes in metabolic functions throughout growth. These complications are largely attributable to inter individual constitutional variations of cellular response to DNA damage.

Subject to radiation-induced DNA damages such as double-strand breaks (DSB), cells reacts by triggering a whole series of phosphorylation events coordinated within multi protein complexes whose interplay is still misknown (DNA damage response i.e. DDR). Indirect Immunofluorescence cell scanning has revolutionized radiation biology research by permitting the detection of individual DSB in each cell nucleus in a dose range from 1 mGy to 10 Gy. This technique has notably confirmed that yield of unrepaired DSB is correlated with cell RS. From a broad spectrum of human radiosensitive skin fibroblast cell lines, the Inserm CRU 1052 team proposed a general model of DSB signaling and repair and a molecular assay to stratify patients according to their individual RS.

ARPEGE biomarqueurs is a prospective multicenter study to prospectively evaluate with this assay the RS of children and adolescents treated over a year in all pediatric oncology departments of the Region Grand Est and set thresholds in this population. 150 children are thus potentially includable in different centers. The assay will be performed on primary fibroblasts cultured from a skin biopsy taken at diagnosis. The RS of patients will be measured in blind. Confusion factors such as irradiated volume, skin phototype, previous chemotherapy regimen, smoking, comorbities (diabetes, immunodeficiency, chronic inflammatory disease ...) will be reported. In parallel the RT-acute toxicity will be reported according to NCI-CTCAE v4.0 reference scale three months of the completion of RT then periodically during 15 years.

Screening hypersensitive patients would be a major step forward in the management of cancers, opening a view to personalized medicine.

Study Timeline

• Study First Submitted: 2016-07-06
• Study First Submitted QC: 2016-07-06
• Study First Posted: 2016-07-11
• Study Start: 2017-03-13
• Primary Completion: 2020-02-07
• Study Completion: 2020-02-07
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-09
• Last Update Posted: 2021-02-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Children < 18 years old
• Patient with an indication of radiotherapy
• Patient must be affiliated to a social security system
• Patient under parental autority
• Ability to provide an informed written consent form

Exclusion Criteria

• Contraindications for skin biopsy
• Contraindications for radiotherapy
• Referred to palliative radiotherapy
• Prior radiotherapy in the same area
• Indication of hypofractionated radiotherapy
• Patient monitoring impossible
• Patients deprived of liberty or under supervision

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
ARPEGE BioM	skin biopsy	N/A (not a randomized study)

Primary Outcome Measures

Name	Time	Method
skin fibroblast radiosenstivity	up to 5 months	residual double-strand breaks 24h after ex vivo radiation assessed with indirect immunofluorescence (gammaH2AX marker).

Secondary Outcome Measures

Name	Time	Method
early cutaneous, mucosal and hematological early radiation toxicity	3 months	early radiation toxicity pattern assessed according to CTACAE v4.0 scale
mean micronuclei number	up to 5 months	micronuclei counted 24 hours after ex vivo radiation assessed with indirect immunofluorescence (DAPI marker).
pATM nucleoshuttling	up to 5 months	pATM foci counted 10 minutes and 1 hour after ex vivo radiation assessed with indirect immunofluorescence (pATM marker).
late radiation toxicity	15 years	deterministic tissue effects as well as secondary malignancies occurring in radiation field more than 3 months and up to 15 years after RT, using CTCAE v4.0 scale

Trial Locations

Locations (11)

CHRU Nancy; 🇫🇷 Vandoeuvre-lès-Nancy, France

CHU de Reims; 🇫🇷 Reims, France

Centre Paul Strauss; 🇫🇷 Strasbourg, France

CHU de Dijon; 🇫🇷 Dijon, France

IUCT Oncopole; 🇫🇷 Toulouse, France

Centre Léon Bérard; 🇫🇷 Lyon, France

CHRU toulouse; 🇫🇷 Toulouse, France

Hôpital de Hautepierre; 🇫🇷 Strasbourg, France

Institut de Cancérologie de Lorraine; 🇫🇷 Vandoeuvre-lès-Nancy, France

CHU de Besançon; 🇫🇷 Besançon, France

Georges-François-Leclerc; 🇫🇷 Dijon, France